Alogliptin and Metformin Fixed-Dose Combination

AssetAlso called Kazano

Fixed-dose combination of DPP-4 inhibitor alogliptin and biguanide metformin.

Stage
Approved
Modality
Small molecule
Target
Not known
2
Indications
1
Trial
1
Developer

Approved by the FDA on Jan 25, 2013 (NDA203414). FDA

Indications

2

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors12
  • Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets